MAR 27, 2019 10:30 AM PDT

The Future of the Cannabis Supply Chain

C.E. Credits: P.A.C.E. CE Florida CE
  • Founder and Chief Executive Officer, Cellibre
      Ben is the founder and CEO of Cellibre, a next-generation biotechnology company that is ushering in the next great industrial revolution by treating biology as a manufacturing technology, turning cells into specialized, sustainable factories for the manufacture of globally significant products at scale. Ben formally worked with Dr. J Craig Venter and Nobel Laureate Dr. Ham Smith as the Vice President of Corporate Development and Strategy at Synthetic Genomics (SGI) where he was responsible for defining, evolving and implementing SGI's strategy across all of its franchises. Ben joined SGI from Millennium Health, a leading medication solutions company focused on solving the opioid epidemic, where he led the strategy and corporate development efforts. Prior to joining industry, Ben had a nine-year tenure on Wall Street, where he executed over $20 billion in transactions. Ben earned his MBA from Carnegie Mellon University's Tepper School of Business and his B.S. in Mechanical Engineering from Case Western Reserve University. He is also the co-founder of Divitempus Ventures, ConvenCare and the 32/21 Foundation.


    Imagine the need for agriculture being removed completely from the cannabis supply chain.

    Cellibre’s vision is to leverage biology to make products more sustainable, efficiently and reliably across industries by employing the multidisciplinary science known as cellular agriculture. We leverage our expertise in cellular agriculture to turn cells into specialized, sustainable factories for the manufacture of globally significant products at scale.

    Cells are inherently superior producers of products for a variety of reasons. First, nature’s machinery can conduct complex reactions at nanoscale precision that are difficult and, in some cases, impossible to achieve by any other means. This ability leads to improved quality and consistency over many legacy manufacturing processes and enable the potential to develop completely novel products. Next, cells copy themselves through cellular division which serves to multiple their natural brick and mortar infrastructure, often with minimal nutrients. This means that production scales itself. In addition, cells repair themselves. Cells have natural machinery that reacts when cell production is impaired to repair the damaged parts and return to regular course. This translates into lower maintenance costs and less downtime. Lastly, cell-based production is uniquely sustainable. Cells very efficiently convert inputs, typically low cost media, into high-value products. In addition, byproducts created as a resulted of bioproduction are generally non-toxic because harmful substances would terminate the cells and stop production of all materials, including the toxins themselves.

    Cellibre's strategic focus is deploying its expertise in cellular agriculture to revolutionize the way cannabis extracts and cannabinoid-based medicines are sourced, produced and consumed. The resultant outputs from the bio-based manufacture of any cannabinoid (including minor cannabinoids) will be high-quality, sustainable and specific cannabinoids for use across applications. The significant deficiencies throughout the current cannabinoid supply chain, the resource requirements in the agricultural process and the evolving regulatory environment globally provide Cellibre an immense opportunity to disrupt a $50+ billion market via the production of high-quality, sustainable, specific and pure, medical-grade natural products.

    Learning Objectives: 

    1. What is cellular agriculture and the science of synthetic biology
    2. Why is fermentation an advantaged method for the production of cannabis extracts on virtually all metrics

    Show Resources
    Show Resources
    • See more